Funding profile · Real-world evidence software

Frekil

A Y Combinator seed-stage startup with no SEC filing on record. What exists instead is a set of third-party trackers that do not agree on how much money it has raised, or from whom.

$500KTotal seed funding, per Tracxn and Standout.work, sourced to Y Combinator
$1.0MAlternate total funding estimate, per Prospeo
2Named investors in the seed round: Y Combinator and 7BC Venture Capital, per a company feature
0SEC Form D filings located for Frekil Inc. as of this profile

Data as of September 25, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Apr 2, 2025 Company founded, per Crunchbase Not applicable Not applicable Independent
Jun 2025 Seed $500,000 Y Combinator Tracker
2025 to 2026 Seed, alternate accounting $1,000,000 total funding Not named Tracker
Not dated Seed, as described in a feature article Not disclosed Y Combinator and 7BC Venture Capital Independent
May 28, 2025 India subsidiary capitalized 10,000 rupees paid up of 1,00,000 authorized Frekil Inc. (parent, per MCA filing category) Public record

What the filings show

No SEC Form D turns up for Frekil Inc., or for any close variant of that name, in a search of EDGAR conducted for this profile. That is not unusual for a company this young: Regulation D filings are due within 15 days of a first sale, and a company that has not yet closed a priced round, or that raised under a different exemption, would have nothing to file yet. It does mean the funding figures below come entirely from secondhand trackers rather than a primary filing.

What is on the public record is the Indian subsidiary. Frekil AI India Private Limited was incorporated on May 28, 2025 with the Registrar of Companies in Bangalore, filed under the Ministry of Corporate Affairs as a subsidiary of a company incorporated outside India, meaning a foreign parent, presumably Frekil Inc., holds it. Its authorized capital is 1,00,000 rupees, about $1,200, and its paid-up capital is 10,000 rupees, about $120. Those are nominal, formation-stage numbers, not a signal of how much capital the group has raised overall; Indian subsidiaries of US-parented startups are routinely capitalized this thinly and funded operationally by the parent instead. The subsidiary’s listed directors are the two co-founders, Nikhil Tiwari and Shivesh Gupta.

Reading the filings

  1. Two trackers, two different totals.Tracxn and Standout.work both put Frekil’s total funding at $500,000 from a single seed round in June 2025, crediting Y Combinator as the investor. Prospeo’s tracker instead lists total funding at $1,000,000. Neither figure is confirmed by a primary filing, and the two do not reconcile: $500,000 is half of $1,000,000, not a rounding difference.
  2. A second investor appears only in a feature article.A YesPress profile of the company states that Frekil “raised seed funding with participation from Y Combinator and 7BC Venture Capital,” without a dollar amount. That is the only source naming 7BC Venture Capital found for this profile. Neither Tracxn nor Standout.work list 7BC as an investor.
  3. No Form D means no confirmed close date.Regulation D notices are the usual way outside observers learn when a seed round actually closed and how much was sold. Without one, “June 2025” for the $500,000 figure is a tracker’s date, not a filing date, and cannot be independently checked.
  4. The India entity is a cost center, not a funding source.Its 10,000-rupee paid-up capital would not cover more than token expenses on its own. Read alongside a Bengaluru registered office and both founders listed as its directors, the more likely picture is a small local operating subsidiary funded by transfers from the US parent, standard structure for an India-based team under a Delaware-style holding company, though Frekil’s own state of incorporation was not confirmed in this research.
  5. The batch name disagreement complicates the funding story too.Y Combinator’s own page places Frekil in its Spring 2025 batch, while other profiles call it X25. Y Combinator’s standard deal terms are public and batch-independent, so this does not change what YC itself would have invested, but it is one more instance of sources describing the same company differently.

Commercial signals

Signal Detail Source type
Product change Launched through Y Combinator in 2025 as a medical-image annotation platform; by 2026 rebuilt entirely around real-world evidence generation from EHR and claims data. Public record
Customers No named pharmaceutical, biotech, or CRO customers found. Three unnamed user testimonials appear on the company site. Company-stated
Press coverage Included in Inc42’s “30 Startups To Watch” for July 2026 and profiled by YesPress, both after the product pivot. Independent
India footprint Registered subsidiary in Bengaluru since May 2025, minimally capitalized, both founders as directors. Public record

What to watch

  • A first SEC Form D for Frekil Inc., which would confirm an actual raised amount and closing date.
  • Whether 7BC Venture Capital’s participation is confirmed anywhere beyond a single feature article.
  • A larger, priced round as the product built around real-world evidence gains customers.
  • Any increase in the Indian subsidiary’s paid-up capital, which would suggest the local entity is being built out rather than kept as a minimal outpost.

The Frekil story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Segmed: Similar focus. A Palo Alto company that collects medical scans from hospitals under revenue sharing deals, strips the identifiers, and sells the result to AI developers and drug
  • Orange Health Labs: Similar focus. An Indian diagnostics company that draws blood at home in under an hour and returns reports in six
  • HelpNow: Similar focus. An app that aggregates private ambulances and converts rideshare cabs into medical first responder vehicles in India
  • Mecha Health: Similar focus. Four University College London researchers built a chest x-ray model that writes the whole report, published benchmarks saying it matches or beats radiologists, and

Sources

  1. Public recordMCA company record, FREKIL AI INDIA PRIVATE LIMITED, CIN U62099KA2025FTC203413Falcon Ebiz, sourced from Ministry of Corporate Affairs
  2. Public recordMCA company record, FREKIL AI INDIA PRIVATE LIMITED, CIN U62099KA2025FTC203413IndiaFilings, sourced from Ministry of Corporate Affairs · last updated Sep 11, 2025
  3. IndependentFrekil funding rounds and investorsTracxn · accessed May 20, 2025
  4. IndependentFrekil profile, funding and founder biosStandout.work · accessed 2026
  5. IndependentFrekil (YC X25) revenue and funding estimateProspeo · accessed May 11, 2025
  6. IndependentFrekil: Real-World Evidence at Software SpeedYesPress · Jul 31, 2026
  7. YC dataFrekil: RWE Generation in minutes, company and founder pageY Combinator · accessed Sep 25, 2026
  8. Independent30 Startups To Watch: Startups That Caught Our Eye In July 2026Inc42 Media, Akshit Pushkarna · Aug 3, 2026
  9. IndependentFrekil organization page, archived snapshot describing the medical-imaging annotation businessCrunchbase, via Wayback Machine · Apr 11, 2025

Compiled from Ministry of Corporate Affairs, SEC EDGAR and other public records and published reports as of September 25, 2026. No SEC Form D for Frekil Inc. was located; funding figures on this page come from third-party trackers and a feature article, and are labeled as such. Healthcare Venture Capital Fund holds no position in Frekil. This page is not an offer to sell or a recommendation to buy any security.